Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Lenvatinib
Related studies linked through entity extraction aliases.
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC
- Status
- COMPLETED
- Phase
- PHASE4
Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)
- Status
- TERMINATED
- Phase
- PHASE2
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
- Status
- COMPLETED
- Phase
- PHASE3
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)
- Status
- COMPLETED
- Phase
- PHASE3
Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure
- Status
- COMPLETED
- Phase
- PHASE2
Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis
- Status
- UNKNOWN
- Phase
- PHASE2
Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
- Status
- COMPLETED
- Phase
- PHASE3
A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma
- Status
- COMPLETED
- Phase
- PHASE2
The Efficacy of Transarterial Chemoinfusion (TAI) Combine Lenvatinib in Advanced Hepatocellular Carcinoma (HCC)
- Status
- UNKNOWN
- Phase
- PHASE3
The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
- Status
- UNKNOWN
- Phase
- PHASE3
Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection
- Status
- WITHDRAWN
- Phase
- PHASE2/PHASE3
HAIC Plus Lenvatinib and Toripalimab for Advanced HCC
- Status
- COMPLETED
- Phase
- PHASE2
Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2